AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02617394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragm scanning - novel method first
Description: The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
Study NCT01549808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
Study NCT01549808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization
Description: sitting, standing and walking
Study NCT00686426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy Foods
Description: Adequate dairy (> 3 standard daily servings)
Study NCT00686426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dairy Foods
Description: \< 1 standard dairy serving/day
Study NCT00904462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study NCT00904462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
Study NCT00937144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viagra (Sildenafil)
Description: Viagra treatment to patients with sickle cell anemia.
Study NCT02040376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
Study NCT02040376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
Study NCT03125343 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Decitabine
Study NCT04511364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical imaging is performed during the 24 and 60 month follow-up visits
Description: X-ray and DXA scan
Study NCT03307863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine-Implant
Description: Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
Study NCT03307863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate-Implant
Description: Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
Study NCT03307863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Mitoxantrone
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Fludarabine
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Idarubicin
Description: Idarubicin
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Venetoclax
Study NCT03926624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Cladribine
Study NCT04612868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEYE Software Device
Description: Eligible participants will undergo the following procedures:~* Photographic imaging of each eye using a funduscopy camera device. Images obtained will be sent to the AEYE-DS software for analysis.~* Additional photographic and Optical Coherence Tomography (OCT) images will be obtained using a second funduscopy/OCT camera device. Images obtained will be sent to a professional reading center for analysis.~* All study subjects will have their pupils dilated using dilation drops.
Study NCT00505336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: oral Eplerenone titrated to 50mg for duration of 12 months
Study NCT00505336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No additional treatment
Description: normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
Study NCT00505336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: oral Atorvastatin 40mg
Study NCT04618250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOFIA model
Description: A mandatory two day course for general practitioners assigned to the intervention group A prolonged consultation at the general practitioner Use of an individual care plan
Study NCT03398876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oromucosal Nicotine Spray (ONS)
Description: Participants will receive oral dose of oromucosal nicotine spray (ONS).
Study NCT03125343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT00937144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02984150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dodecanoic acid
Study NCT04427709 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin
Description: Intramuscular injection of Oxytocin (Pitocin®)
Study NCT04427709 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Intramuscular placebo injection
Study NCT04106466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Summit RC+S DBS system
Description: Open label active Deep Brain Stimulation (DBS)
Study NCT03125343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Study NCT04160091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006
Description: Single intra-articular injection
Study NCT03398876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: Participants will chew nicotine gum for 30 minutes.
Study NCT03398876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: Participants will smoke one cigarette as 10 puffs for 3 minutes.
Study NCT02984150 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: saline
Study NCT01581216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 minute walk
Description: Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
Study NCT01581216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 minute walk
Description: Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
Study NCT01581216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30 minute walk
Description: Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
Study NCT02208414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAET
Description: NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
Study NCT02760173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perception of vertical after static roll-tilt over 5min
Description: subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
Study NCT01607333 — intervention group
Intervention type: DRUG
Intervention: Lamotrigine use
Description: Lamotrigine prescription during the study period
Study NCT03319953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-041
Description: TAK-041 suspension
Study NCT03319953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-041 placebo-matching suspension
Study NCT03319953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Second Generation Antipsychotics (SGA)
Description: Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
Study NCT02696733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided obturator nerve localization
Study NCT02696733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine 2%
Description: local anesthetic used to block the obturator nerve
Study NCT02696733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Natrium Chloratum with a 2nd generation cephalosporin
Study NCT03459001 — intervention group
Intervention type: OTHER
Intervention: Tube Feeding Product
Description: a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
Study NCT01568450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone XL 20mg(20mg once a day, fasted)
Study NCT01568450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
Study NCT01568450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Oxycodone 20mg/day (10mg twice a day, fasted)
Study NCT03648177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPGT
Description: Behavioral Intervention for Patients with Chronic Pain
Study NCT03648177 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard Care
Study NCT04160091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single intra-articular injection
Study NCT01003730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator settings
Description: Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
Study NCT01795495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride
Description: This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
Study NCT01795495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
Study NCT01795495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Study NCT04069611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
Study NCT04069611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
Study NCT04069611 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scaling and root planing
Description: Mechanical debridement with US and curettes of hard and soft plaque deposits
Study NCT00433160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teriparatide
Description: daily, subcutaneous
Study NCT00433160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: daily, subcutaneous
Study NCT00433160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily, subcutaneous
Study NCT04710355 — intervention group
Intervention type: DEVICE
Intervention: Spinal cord stimulation
Description: Adhesion of Intellis spinal cord stimulator to the skin of the abdomen for 4 weeks for baseline recording of activity level prior to trial with spinal cord stimulation.
Study NCT06163183 — intervention group
Intervention type: DEVICE
Intervention: Edi catheter
Study NCT02975011 — intervention group
Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
Study NCT01799369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surgical Apgar Score
Description: Post-operative care influenced by Surgical Apgar Score
Study NCT02068092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol
Study NCT02975011 — intervention group
Intervention type: PROCEDURE
Intervention: Chuna manipulation
Description: Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
Study NCT02975011 — intervention group
Intervention type: PROCEDURE
Intervention: Bee venom pharmacopuncture
Description: Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
Study NCT02975011 — intervention group
Intervention type: PROCEDURE
Intervention: Pharmacopuncture
Description: Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
Study NCT02975011 — intervention group
Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
Study NCT02975011 — intervention group
Intervention type: PROCEDURE
Intervention: Electroacupuncture
Description: Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
Study NCT02975011 — intervention group
Intervention type: PROCEDURE
Intervention: Cupping
Description: Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
Study NCT02975011 — intervention group
Intervention type: OTHER
Intervention: Other intervention(s)
Description: Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
Study NCT01045148 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Radiosurgery
Description: High Dose 3800 cGy/4 fractions
Study NCT01045148 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: CyberKnife Radiosurgery
Description: Moderate Dose 3400 cGy/5 fractions
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, SC, or IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT, SC, or IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT04069611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Mechanical debridement with US and curettes of hard and soft plaque deposits
Study NCT02998593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bahman capsules
Description: Oral Use of Bahman capsules for 3 months by patients.
Study NCT02998593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral use of placebo capsules by patients for 3 months.
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT01011634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous moderate sedation versus oral medication
Description: Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
Study NCT02091544 — intervention group
Intervention type: OTHER
Intervention: Lifestyle intervention
Study NCT00309387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Centrum
Description: Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
Study NCT00309387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets manufactured to mimic Centrum tablets.
Study NCT00560976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Saccharate (Venofer)
Description: Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
Study NCT02208414 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NAET
Description: NAET with acupressure and/or chiropractic procedures with the participant holding water vial
Study NCT00743574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (Ergocalciferol)
Description: 50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
Study NCT00743574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (Provera)
Description: 10mg, PO, daily for ten days
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT or IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT or IV
Study NCT00075725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IM